BREAKING
Monte Rosa (GLUE) Reports Wider Q4 Loss of $0.55/Share vs $0.34 Estimate, Revenue Misses 4 minutes ago Monte Rosa Therapeutics, Inc. (GLUE) Reports Wider Loss Q4 EPS Estimates by 63.4% 8 minutes ago Coda Octopus (CODA) Beats Q1 Estimates with $0.08 EPS, Revenue Surges 28.6% YoY to $6.7M 19 minutes ago Bicycle Therapeutics (BCYC) Q4 Revenue Soars 1194.5% YoY to $48M, Crushing Estimates by 578% 21 minutes ago Getty Images (GETY) Q4 Revenue Surges 14.1% YoY to $282.3M 42 minutes ago FINV Stock: 8 Analysts Issue Buy-or-Better Ratings as FinVolution Delivers $0.25 EPS on Flat Revenue 1 hour ago Semtech (SMTC) Beats Q4 EPS Estimates by 2.0% with $0.44 Earnings, Revenue Climbs 9.3% YoY 1 hour ago Dragonfly Energy (DFLI) Posts $14.92 Loss Per Share for Q4, Revenue at $13.1M 1 hour ago Microvast (MVST) Q4 Revenue Falls 15% to $96.4M, Adjusted EPS Loss of $0.11 Misses Estimates 2 hours ago BW Swings to Profit with $0.05 EPS, Beating Estimates by 134.4% on $161M Revenue 2 hours ago Monte Rosa (GLUE) Reports Wider Q4 Loss of $0.55/Share vs $0.34 Estimate, Revenue Misses 4 minutes ago Monte Rosa Therapeutics, Inc. (GLUE) Reports Wider Loss Q4 EPS Estimates by 63.4% 8 minutes ago Coda Octopus (CODA) Beats Q1 Estimates with $0.08 EPS, Revenue Surges 28.6% YoY to $6.7M 19 minutes ago Bicycle Therapeutics (BCYC) Q4 Revenue Soars 1194.5% YoY to $48M, Crushing Estimates by 578% 21 minutes ago Getty Images (GETY) Q4 Revenue Surges 14.1% YoY to $282.3M 42 minutes ago FINV Stock: 8 Analysts Issue Buy-or-Better Ratings as FinVolution Delivers $0.25 EPS on Flat Revenue 1 hour ago Semtech (SMTC) Beats Q4 EPS Estimates by 2.0% with $0.44 Earnings, Revenue Climbs 9.3% YoY 1 hour ago Dragonfly Energy (DFLI) Posts $14.92 Loss Per Share for Q4, Revenue at $13.1M 1 hour ago Microvast (MVST) Q4 Revenue Falls 15% to $96.4M, Adjusted EPS Loss of $0.11 Misses Estimates 2 hours ago BW Swings to Profit with $0.05 EPS, Beating Estimates by 134.4% on $161M Revenue 2 hours ago
ADVERTISEMENT
Breaking News

Bicycle Therapeutics (BCYC) Q4 Revenue Soars 1194.5% YoY to $48M, Crushing Estimates by 578%

Bicycle Therapeutics narrows Q4 loss to $0.29/share vs $0.95 estimate; revenue of $48M crushes $7.1M consensus by 578%.

March 17, 2026 2 min read

Bicycle Therapeutics narrows Q4 loss to $0.29/share vs $0.95 estimate; revenue of $48M crushes $7.1M consensus by 578%.

Earnings Per Share (GAAP)
$-0.29
vs $-0.95 est.
Revenue
$48.0M
vs $7.1M est.
What to Watch: The company’s ability to sustain this revenue trajectory in Q1 2026 will determine whether the $48 million quarter represents a new baseline or a one-time milestone payment. Watch for management commentary on the earnings call regarding revenue composition and forward guidance.

This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.

ADVERTISEMENT
Tags: #BCYC